These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 34519692)

  • 21. Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancer.
    Karpel HC; Smith M; Brodsky A; Pothuri B
    Gynecol Oncol; 2023 Aug; 175():20-24. PubMed ID: 37290248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation-specific Mismatch Repair-deficient Benign Endometrial Glands in Endometrial Biopsies and Curettings Are a Biomarker of Lynch Syndrome and Associate With Endometrial Carcinoma Development.
    Hegazy S; Brand RE; Dudley B; Karloski E; Lesnock JL; Elishaev E; Pai RK
    Am J Surg Pathol; 2023 Jul; 47(7):835-843. PubMed ID: 37226842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 26. Somatic Testing on Gynecological Cancers Improve the Identification of Lynch Syndrome.
    Carnevali I; Libera L; Chiaravalli A; Sahnane N; Furlan D; Viel A; Cini G; Cimetti L; Rossi T; Formenti G; Ghezzi F; Riva C; Sessa F; Tibiletti MG
    Int J Gynecol Cancer; 2017 Sep; 27(7):1543-1549. PubMed ID: 28471861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
    Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
    J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE
    Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome.
    Helderman NC; Andini KD; van Leerdam ME; van Hest LP; Hoekman DR; Ahadova A; Bajwa-Ten Broeke SW; Bosse T; van der Logt EMJ; Imhann F; Kloor M; Langers AMJ; Smit VTHBM; Terlouw D; van Wezel T; Morreau H; Nielsen M
    J Mol Diagn; 2024 Feb; 26(2):106-114. PubMed ID: 38061582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial screening by immunohistochemistry is effective in universal screening for Lynch syndrome in endometrial cancer patients: a prospective observational study.
    Tsuruta T; Todo Y; Yamada R; Kuwahara K; Kurosu H; Minowa K; Minoura Y; Minobe S; Suzuki H; Kato H
    Jpn J Clin Oncol; 2022 Jul; 52(7):752-758. PubMed ID: 35438162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach.
    Dondi G; Coluccelli S; De Leo A; Ferrari S; Gruppioni E; Bovicelli A; Godino L; Coadă CA; Morganti AG; Giordano A; Santini D; Ceccarelli C; Turchetti D; De Iaco P; Perrone AM
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
    Long Q; Peng Y; Tang Z; Wu C
    Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome.
    Canet-Hermida J; Marín F; Dorca E; Dueñas N; Costas L; Salinas M; Velasco À; Peremiquel-Trillas P; Paytubi S; Ponce J; Fernández S; Martínez JM; Cárdenas L; Taltavull A; Alemany L; Meléndez C; Oliveras G; Vidal A; Capellá G; López-Bonet E; Brunet J; Matias-Guiu X; Pineda M
    Mod Pathol; 2023 Jul; 36(7):100158. PubMed ID: 36918055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.
    Moline J; Mahdi H; Yang B; Biscotti C; Roma AA; Heald B; Rose PG; Michener C; Eng C
    Gynecol Oncol; 2013 Jul; 130(1):121-6. PubMed ID: 23612316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mismatch repair deficiency testing in clinical practice.
    Buza N; Ziai J; Hui P
    Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome.
    Adar T; Rodgers LH; Shannon KM; Yoshida M; Ma T; Mattia A; Lauwers GY; Iafrate AJ; Hartford NM; Oliva E; Chung DC
    Cancer; 2018 Aug; 124(15):3145-3153. PubMed ID: 29750335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.
    Sari A; Pollett A; Eiriksson LR; Lumsden-Johanson B; Van de Laar E; Kazerouni H; Salehi A; Sur M; Lytwyn A; Ferguson SE
    Am J Surg Pathol; 2019 May; 43(5):591-600. PubMed ID: 30864976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.